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B Cell Responses to a Peptide Epitope. V. Kinetic Regulation
of Repertoire Discrimination and Antibody Optimization for
Epitope1
Bishnu P. Nayak,* Renu Tuteja,* Venkatasamy Manivel,* Rajendra P. Roy,†
Ram A. Vishwakarma,† and Kanury V. S. Rao2*
The influence of imposing various conformational constraints on immune responses to a model epitope within a synthetic peptide
immunogen was examined in mice. Although overall immunogenicity was affected, the model epitope (sequence DPAF) remained
the predominant recognition site regardless of the conformation in which it was presented. A comparison of anti-DPAF mAbs
obtained in response to two analogue peptides, PS1CT3 and CysCT3, in which the DPAF segment was either unconstrained or held
within a cyclic loop, respectively, revealed a significant homology in the paratope composition. At one level a subset of anti-PS1CT3
and anti-CysCT3 mAbs was found to share a common heavy chain variable region. In addition, nucleotide sequence homology
comparisons of both heavy and light chain variable regions identified the presence of anti-PS1CT3 and anti-CysCT3 mAbs that
collectively appeared to derive from a common progenitor, but with nonidentical somatic mutations. Interestingly, however, no
bias toward homologous Ag could be discerned on measurement of relative affinities of the mAbs for the two peptides. In contrast,
mAb binding on-rates clearly discriminated between peptides representing the homologous vs the heterologous confomer of the
DPAF epitope. Thus, it would appear that the kinetics of Ag recognition dominate over equilibrium binding criteria both in
epitope-driven repertoire selection and Ab maturation in a humoral response. The Journal of Immunology, 1998, 161: 3510–3519.
T he antigenicity of domains on protein Ags has long beensuspected to result from a variety of biophysical proper-ties, such as backbone mobility, side chain stereochemis-
try, solvent accessibility, shape, secondary or three-dimensional
structure, and local hydrophilicity (reviewed in Ref. 1). The un-
derlying basis for such assumptions has been founded on the fact
that B cells generally recognize protein Ags in their native form
(1). Given that the preimmune B cell repertoire is not limiting (2),
accessibility or easy availability for B cell recognition seemed to
be the only intrusive criterion in identifying a B cell epitope. As a
result, it was therefore logical to seek parameters that may help
determine either surface exposure or ready accessibility of do-
mains in a folded protein as direct correlates of antigenicity (3–8).
Recent results from our laboratory, however, have identified an
additional constraint that intervenes to eventually determine the
immunodominance of a given B cell epitope. We have shown that
while the early primary T-dependent IgM response was indeed
consistent with expectations, in that Abs were produced against all
accessible domains, subsequent progression entailed stringent se-
lection for only a restricted subset from the initially induced poly-
clonal pool (9). Positive selection of Ab specificities was found to
be regulated by the ability of individual clonotypes to recruit the
appropriate level of help, in a competitive environment, from a
limiting pool of early Ag-activated Th cells (10). This, in turn, was
dependent on both equilibrium (11, 12) and kinetic (13) binding
properties of B cell surface Ig (sIg)3 receptor recognition of its
epitope on Ag, critical prognosticators that describe the Ag-pre-
senting efficacy of a B cell. Thus, immunologic parameters impli-
cated in modulating immunogenicity appear to prevail over deter-
minants of antigenicity to eventually define the functional identity
of putative B cell epitopes on polypeptide Ags.
The model antigenic determinant employed for the above stud-
ies was a 15-residue sequence (segment PS1) derived from the
large envelope protein of hepatitis B surface Ag (HBsAg), in con-
junction with one or more well-characterized T cell epitopes (12).
We observed that the murine primary IgG response to such model
immunogens was always directed exclusively against a tetrapep-
tide sequence (sequence: DPAF) encoded between positions 4 and
7 of the PS1 domain (10–13). The immunodominance of the
DPAF sequence was independent of either the nature or the num-
ber of T cell epitopes included (10, 12). It was also independent of
the position of the PS1 segment within the immunogen sequence
(i.e., at the amino-terminal, middle, or carboxyl-terminal positions)
(12). Finally, immunodominance of the DPAF epitope was also
established in immunogen sequences of random structure, as de-
termined by circular dichroism (CD) spectroscopy (12, 13), im-
plying that accessibility for recognition was not the sole selection
criterion. Such synthetic peptide antigens therefore represent good
model systems to further understand both biophysical and immu-
nologic parameters that help determine the immunodominance of
a given B cell epitope.
Using analogues of a model peptide with different secondary
structural propensities, we show here that immunodominance is
independent of either perturbation in conformational preferences
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or overall immunogenicity. Furthermore, both Ag-dependent rep-
ertoire discrimination and subsequent adaptation of Ab for optimal
Ag binding appear to be regulated by the rapidity of binding rather
than by the stability of it.
Materials and Methods
Materials
Horseradish peroxidase-labeled anti-mouse IgG (heavy chain specific)
were purchased from Sigma (St. Louis, MO). F-moc amino acid derivatives
were purchased from Novabiochem (Laufelfingen, Switzerland). For mul-
tipin synthesis of peptides, the noncleavable kits were obtained from Chi-
ron Mimotopes (Victoria, Australia).
Peptide synthesis
Peptides were synthesized on a Milligen 9050 automated peptide synthe-
sizer (Millipore, Bedford, MA) using F-moc chemistry (14–16). Crude
peptides were purified to at least 95% purity by reverse phase HPLC on a
C18 column (15 mm, dPak, 19 3 300 mm; Waters, Milford, MA). The
identities of all peptides were ascertained by amino acid analysis.
For the synthesis of peptide CysCT3, the side chain protecting group
used for cysteine was the acetamidomethyl group. Subsequent to synthesis
and cleavage from the solid support, simultaneous deprotection of cysteine
side chains and oxidation to form intramolecular disulfide bonds were
achieved with iodine in acetic acid (17). Briefly, 70 mg of the acetamidom-
ethyl-derivatized peptide was dissolved in 4 ml of 50% aqueous acetic acid.
To this was added 1 ml of 1 M hydrochloric acid, followed immediately by
40 ml of a 50-mM solution of iodine in 50% aqueous acetic acid. After 30
min of vigorous stirring, the reaction was quenched with 2 ml of 1 M
aqueous sodium thiosulfate. This was then concentrated in vacuo, follow-
ing which it was passed over Celite. The resulting solution was lyophilized
to yield the crude product, which was purified by reverse phase HPLC as
described above. In addition to amino acid analysis, the correct identity of
peptide CysCT3 could be established by mass spectrometry (expected
mass, 3965; experimentally obtained mass, 3964.2).
Overlapping hexapeptide panels were synthesized by the method of
Geysen (18) using the multipin noncleavable kits (Chiron Mimotopes, Vic-
toria, Australia), strictly adhering to the protocol of the manufacturer. After
completion of synthesis, all peptides were routinely acetylated at the amino
terminus and subsequently deprotected as previously described (12).
Animals and immunizations
Female BALB/c mice (6–8 wk old) were obtained from the small animal
facility at the National Institute of Nutrition (Hyderabad, India). Immuni-
zations were given i.p. at a dose of 50 mg/mouse as an emulsion in CFA.
For polyclonal sera, mice were bled from the retro-orbital plexus, and sera
within a group were pooled.
Preparation of anti-CysCT3 IgG mAbs
A group of four BALB/c mice was immunized with a single dose of pep-
tide CysCT3 as described above. Twenty-eight days later they were
boosted with 50 mg/mouse of soluble peptide CysCT3 in PBS given i.v.
Three days later, the highest responder from the group was taken for the
generation of IgG-secreting hybridomas. Polyethylene glycol-mediated fu-
sion to hypoxanthine-aminopterin-thymidine-sensitive myeloma deriva-
tive, SP2/O-Ag 14, maintenance of derived cell lines, and limiting dilution
cloning were essentially as previously described (12, 19). The secretion of
Ab in culture supernatants was screened by ELISA against wells coated
with peptide CysCT3.
ELISAs
Plates were coated with 2 mg/well in 100 ml of PBS (pH 7.2) at 37°C for
3.5 h. Subsequently, they were blocked with 300 ml/well of a 5% solution
of fat-free dry milk powder in PBS at 37°C for 1 h. Then, 100 ml of the
appropriate dilution of mouse antiserum was added and incubated at 37°C
for 1 h. After washing, bound Ab was detected with horseradish peroxi-
dase-labeled secondary Ab (37°C, 1 h), followed by color development
with o-phenylenediamine. Absorbance was measured at 490 nm.
For competitive ELISA experiments, antisera were used at dilutions
representing 50% of the titer value. Twofold higher concentrations of an-
tiserum and competitor peptide were mixed in equal volume and incubated
for 10 min at room temperature. This was then added to duplicate wells at
100 ml/well. The remaining procedure was as described above.
ELISA assays for pin-bound peptides
The protocol for ELISA-based screening of Ab cross-reactivity with the
overlapping hexapeptide panels has been described previously (12).
Briefly, primary Abs were diluted to appropriate concentrations in PBS
containing 2% BSA, 0.1% (v/v) Tween-20, and 0.1% (w/v) sodium azide.
Pins were incubated in 200 ml each of Ab solution at 4°C overnight with
gentle shaking. Subsequently, after washing they were then incubated with
horseradish peroxidase-labeled goat anti-mouse IgG at room temperature
for 1 h with gentle shaking. The chromogen used for revealing bound Ab
was 2,29-azino-bis-(3-ethylbenzthiazoline-6-sulfonic acid) diammonium,
and absorbance was measured at 405 nm with subtraction of that at 490 nm.
Determination of on-rates and dissociation constants
On-rates of mAb binding to either peptide PS1CT3 or CysCT3 were de-
termined as previously described (13). Briefly, equal volumes of mAb and
appropriate peptide in PBS were mixed at room temperature, and time-
dependent Ab binding in terms of quenching of tryptophan fluorescence
was continuously monitored over a 100-min period in a Shimadzu RF-1501
spectrofluorometer (Shimadzu, Tokyo, Japan). The excitation wavelength
used was 280 nm, and emission was recorded at 330 nm. The final Ab
concentration employed was between 200 and 300 nM, whereas peptide
was maintained at between 10- and 25-fold in molar excess over binding
sites (assuming bivalency per Ab molecule) to ensure pseudo-first-order
conditions. The extent of fluorescence quenching was used to determine
unbound Ab concentrations as a function of time. The log of the concen-
tration of unbound Ab was plotted vs time, and the slope, which was
obtained by linear regression analysis, was used to determine kapp. The kon
value was subsequently calculated by dividing kapp by the peptide concen-
tration. Values of kon presented are the mean (6SD) of determinations at
three independent peptide concentrations.
For dissociation constants, mAbs (final concentration between 100–150
mM) were incubated alone or with either peptide PS1CT3 or CysCT3 at
concentrations ranging from 5 3 1025 to 1 3 1029 M at room temperature
for 1 h. Subsequent to this extent of quenching of tryptophan, fluorescence
was determined, from which the concentration of peptide bound was cal-
culated assuming bivalency for each IgG molecule at saturation. Kd values
were subsequently obtained from a Scatchard analysis of the resulting data.
Nuclear magnetic resonance (NMR) spectroscopy
Natural abundance, proton-decoupled (Waltz 16 decoupler) 13C NMR
spectra were recorded in a mixture of H2O and D2O (9:1) on a Brucker
(Avance Series, DRS 300, Billerica, MA) spectrometer at 75.47 MHz. The
spectral width was maintained at 19,607.84 Hz, with a time domain size of
65K. A total of 15,000 scans were accumulated at 300°K, using 3-(tetra-
methylsilyl)-1-propane sulfonic acid as the reference standard.
RT and amplification of IgG mRNA
Total cellular RNA was isolated from about 107 hybridoma cells with an
RNAzol (Wak-Chemie Medical, Homburg, Germany)-based protocol with
minor modifications. About 10 mg of total RNA was used for each V gene
cDNA amplification. The first strand of cDNA was synthesized using 20 U
of reverse transcriptase (Promega, Madison, WI) and 800 pmol of the
primer, 59-GGCCAGTGGATAGAC-39 for Cg and 59-GCTCACTGGAT
GGTGGGAAGATG-39 for Ck, in a final volume of 25 ml. Single-stranded
cDNA was then amplified using as 59 primer, 59-AGGT(C/G)(A/C)A(A/
G)CTGCAG(G/C)AGTC(A/T)GG-39 for VH and 59-GA(A/C/T)ATT
GTG(A/C)T(G/C)AC(A/C)CA(A/G)(A/T)CTCCA-39 for VL. A different
set of nested 39 primers was used for amplification, 59-GGCCAGTGGATA
GAC(T/C/A)GA-39 for Cg and 59- GAAGATGGATACAGTTGGT
GCA-39 for Ck. Amplification was conducted using 5 ml of cDNA and Taq
polymerase (Stratagene, La Jolla, CA) in a final volume of 100 ml. The
final concentrations of reagents were 50 mM KCl, 10 mM Tris-HCl (pH
8.8), 1.5 mM MgCl2, 0.01% gelatin, 200 pmol of each primer, and 2.5 U
of Taq polymerase. PCR was performed on a Perkin-Elmer thermocycler
using the following program: one cycle at 95°C for 3 min, followed by 30
cycles of 1 min each at 94°C, 58°C for 1.5 min, 72°C for 1 min, and finally
a 10-min incubation at 72°C. A 10-ml aliquot of the reaction mixture was
analyzed on a 1.8% agarose gel.
Nucleotide sequencing of the PCR-amplified DNA
PCR products of about 400 bp were blunt ended by polishing with the PCR
polishing kit from Stratagene and were subsequently cloned in the SrfI site
of PCR-script vector of the PCR-script cloning kit from Stratagene. Posi-
tive clones were identified, restriction digestion of plasmid DNA was per-
formed, and appropriate clones were sequenced using the T7 sequencing
kit purchased from Pharmacia (Uppsala, Sweden). Both strands of cloned
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DNA were sequenced. Normally two independent clones were sequenced
for each mAb. However, in instances where any discrepancy was noted,
additional clones were sequenced to rule out artifactual mutations as a
result of the PCR procedure. The Ig heavy and light chain variable region
gene sequences were analyzed using PC Gene software (Oxford Molecular
Group PLC, Oxford, U.K.) and the GenBank data library.
Results
Peptide PS1CT3 and its analogues
The model parent immunogen (peptide PS1CT3; Fig. 1A) used in
these studies has been described previously (10, 12, 14). Briefly, it
represents a hybrid of a B cell epitope derived from the envelope
protein of HBsAg (20) and a promiscuous T cell epitope resident
within the circumsporozoite protein of the malaria parasite, Plas-
modium falciparum (21). We have shown in prior studies that this
peptide represents a T-dependent Ag and that immunization in
BALB/c mice results in a primary and a secondary IgG response
that is exclusively directed against a tetrapeptide sequence be-
tween positions 4 and 7 (sequence: DPAF) (12). Furthermore,
based on a combination of results derived from an analysis of early
primary IgM responses to peptide PS1CT3 and the CD spectrum of
peptide, it was inferred that surface accessibility alone was an in-
sufficient criterion to explain the immunodominance of the DPAF
segment within peptide PS1CT3 (12).
To probe further whether altered conformational constraints of
an epitope influences its immunodominance, we synthesized two
additional analogues of peptide PS1CT3, namely, peptides
AibCT3 and CysCT3 (Fig. 1A). Peptide AibCT3 represents an an-
alogue where the amino acid residues at positions 1 and 10 in the
parent sequence were substituted with a-aminoisobutyric acid
(Aib), a nonnatural amino acid known to promote a-helix forma-
tion when introduced into peptide sequences (22). That Aib sub-
stitution also confers a propensity for helix formation in the
present instance could be confirmed with the help of a synthetic
peptide representing the B cell epitope segment (positions 1–15) of
peptide AibCT3 (peptide Aib-PS1). Analysis of the CD spectra of
this peptide in the presence of varying concentrations of the sec-
ondary structure-enhancing solvent, trifluoroethanol (TFE) (23),
revealed ready inducibility into an a-helix (Fig. 1B, a). The second
FIGURE 1. A, Amino acid sequence of peptide PS1CT3 and its analogues. The amino acid sequence of peptide PS1CT3 and its two analogues, peptides
AibCT3 and CysCT3, are given here in the single letter code for amino acids. The His and Asn residues at positions 1 and 10 of the PS1CT3 sequence
(underlined) have been replaced by Aib residues (indicated by the symbol X) in peptide AibCT3 and by Cys in peptide CysCT3. Residues 1 to 15 of the
PS1CT3 peptide (segment PS1) correspond to a known B cell epitope of HBsAg, whereas residues 18 to 38 (segment CT3) constitute a promiscuous T
cell epitope from the circumsporozoite protein of P. falciparum (12). Separating the B and T cell epitopes is a spacer of two glycine residues at positions
16 and 17. The immunodominant sequence, DPAF, in peptide PS1CT3 is highlighted within a box. The double bond between the Cys residues in peptide
CysCT3 is meant to denote a disulfide bond. B, CD spectra of peptides Aib-PS1 (a) and PS1 (b) in aqueous and secondary structure-enhancing solvents.
The CD spectra of peptide Aib-PS1 at a final concentration of 6 mM was recorded on a JASCO model J710 spectropolarimeter (JASCO, Tokyo, Japan)
over a wavelength range of 200 to 250 nm with a step resolution of 0.1 nm and a scan speed of 200 nm/min. The spectra shown are those averaged over
a total of 30 accumulations. a shows the CD spectra of peptide Aib-PS1 either in 0.01 M phosphate buffer (pH 7.2) alone (- - -) or in buffer containing
10% (- z -), 20% (- zzz -), or 50% (—-) of TFE. Panel b shows the CD spectra obtained for a peptide representing the B cell epitope segment (residues 1–15)
of the parent peptide PS1CT3 (peptide PS1) under identical conditions. This has been included for comparative purposes. In the latter case the profiles
obtained in buffer alone and in the presence of 10% TFE were superimposable. As is evident, peptide Aib-PS1 shows a markedly greater helix-forming
potential than peptide PS1. This is further supported by the occurrence of an isodichroic point in panel a at about 204 nm, which is indicative of
TFE-dependent transition from random to a helical structure. No such isodichroic point is observed in the CD spectra of peptide PS1 (b).
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analogue, peptide CysCT3, was one in which the residues at po-
sitions 1 and 10 were substituted with cysteines, subsequent to
which this segment was locked into a loop by oxidation to generate
a disulfide bond (Fig. 1A). Thus, while the immunodominant
DPAF segment exists in a disordered conformation in peptide
PS1CT3, it is conferred with an a-helical propensity in peptide
AibCT3. In contrast, this segment was expected to be held within
a relatively rigid cyclic loop in peptide CysCT3.
We were further able to verify that the substitutions performed
do, in fact, variably influence conformational distributions of the
DPAF epitope by NMR spectroscopy. While a detailed analysis
will be published elsewhere (R. A. Vishwakarma, et al., manu-
script in preparation), Figure 2 shows two relevant regions of pro-
ton-decoupled, natural abundance 13C NMR spectra of peptides
PS1, Aib-PS1, and Cys-PS1. Figure 2A represents that portion of
the spectrum that includes the chemical shifts for the a-carbon
atoms of proline residues. In peptide PS1 (top panel), the signal for
the a-carbon of the proline residue at position 14 appears at
61.1314 ppm (peak 2), whereas that for the residue within the
DPAF epitope (Pro5) is further upfield at 61.0344 ppm (peak 3).
Peaks 1 and 4 (66.9532 and 60.6537 ppm) correspond to the b- and
a-carbons of the threonine residue at position 12 in the PS1 se-
quence. A comparison with the corresponding region of the spec-
trum for peptide Aib-PS1 (middle panel) reveals an interesting
difference with respect to the a-carbon of the proline residue
within the DPAF sequence (Pro5). In the latter case an upfield shift
to 60.8712 ppm was observed. Furthermore, this signal displayed
multiplicity (Fig. 2A, middle panel), indicative of the existence of
this carbon atom in a multiplicity of chemical environments, all of
which were nonidentical with that for the corresponding carbon
atom in peptide PS1. In contrast, the a-carbon of Pro5 in peptide
Cys-PS1 (Fig. 2A, bottom panel) was shifted downfield to merge
with the signal for the a-carbon of Pro14. While the signal for the
a-carbon of Pro5 was variably shifted depending upon either Aib
or Cys substitution, the signals for the corresponding carbon atoms
in Pro14 and Thr12 remained invariant among the three analogues
(Fig. 2A).
Figure 2B gives the aromatic region of the 13C NMR spectra of
these peptides. The top panel is that for peptide PS1, where peak 1
represents the carbon at position 1 (with respect to b-carbon substi-
tution) of the benzene ring of phenylalanine. Peaks 2 and 3 correspond
to the ortho and meta aromatic carbons, respectively, whereas peak 4
represents the carbon in the para position. The remaining two signals
are derived from the carbons in the imidazole ring of histidine, which
are absent in peptides Aib-PS1 (middle panel) and Cys-PS1 (bottom
panel). Although the distribution of signals for the aromatic carbons
of Phe remain unchanged in the spectrum of peptide Aib-PS1, that for
peptide Cys-PS1 reveals interesting differences (Fig. 2B, bottom pan-
el). Signals for the aromatic carbons at both the 1 and ortho positions
displayed multiplicity in the case of peptide Cys-PS1, indicative of
differences in the chemical environment of the Phe residue in peptides
PS1 and Cys-PS1.
Collectively, the data in Figure 2 clearly demonstrate that both
Aib and Cys substitutions nonidentically perturb the stereochem-
ical environment of the DPAF epitope with respect to that in pep-
tide PS1.
FIGURE 2. Proton-decoupled 13C NMR spectra of peptides PS1, Aib-PS1, and Cys-PS1. For details refer to Materials and Methods and the text.
Assignments of individual carbon atoms were performed with the help of published values for chemical shifts (53). Any ambiguity was resolved by
obtaining spectra for the individual amino acids. The a-carbon atoms of the two proline residues at positions 5 and 14 were distinguished by heteronuclear
multiple quantum coherence experiments. The identity of the extra signal at 61.4748 ppm for peptide Cys-PS1 in A remains presently unknown as does
the reason for diffusion of the peak corresponding to the b-carbon of Thr12.
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Relative immunogenicity of peptides PS1CT3, AibCT3, and
CysCT3
Our initial studies were directed toward examining the effects of
these modifications on the immunogenicity of the resulting pep-
tides. For this, peptide PS1CT3 and its two analogues were inde-
pendently immunized into groups of BALB/c mice, and the result-
ing specific IgG titers were monitored. As shown in Figure 3,
secondary structure, or a preference for it, can influence immuno-
genicity. While Aib substitution resulted in a marginal enhance-
ment of Ab titers, peptide CysCT3 was only weakly immunogenic
(Fig. 3). More recent studies have indicated that the poor immu-
nogenicity of peptide CysCT3 is a consequence of its poorer abil-
ity to prime Th cells (B. P. Nayak and K. V. S. Rao, unpublished
observations).
Epitope specificity of the primary IgG response is independent
of conformational constraints
We have shown earlier that the murine primary response to peptide
PS1CT3 was exclusively directed against the B cell epitope seg-
ment (segment PS1) between positions 1 and 15, with no detect-
able Abs against the rest of the sequence (12). To confirm whether
this was also true for peptides CysCT3 and AibCT3, we performed
competitive inhibition ELISA experiments in which binding of day
28 IgG with either CysCT3 or AibCT3 was examined in the pres-
ence of either the homologous immunogen or a synthetic peptide
representing only the homologous B cell epitope segment (residues
1–15) as inhibitor. The results from such an experiment are shown
in Figure 4, where parallel data obtained for anti-PS1CT3 IgG is
also included for comparison. Nearly identical inhibition profiles
were obtained regardless of whether the whole homologous im-
munogen or only its derived B cell epitope segment was used as
inhibitor, with virtually complete inhibition at higher concentra-
tions. Further, a synthetic peptide representing the T cell epitope
segment (residues 18–38) was also unable to inhibit Ab binding to
any significant extent over the dose range tested in any of the cases
(,10%; data not shown). Collectively, these results suggest that,
similar to peptide PS1CT3, the specificity of primary IgG re-
sponses to peptides AibCT3 and CysCT3 is also at least predom-
inantly restricted to within the amino-terminal 15 residues, with
little or no response against the rest of the Ag sequences.
To further localize fine specificities, we resorted to epitope map-
ping with a panel of overlapping hexapeptides, displaced by one
residue at a time, derived from the B cell epitope segment of each
of these analogues. The results from such an experiment are shown
in Figure 5. The cross-reactivity profile obtained with anti-PS1CT3
IgG is entirely consistent with our earlier observation, in that only
three overlapping peptides (sequences: QLDPAF, LDPAFG, and
DPAFGA) were recognized (12). This was shown to result from
virtual monospecificity of the IgG response against a common tet-
rapeptide sequence, DPAF (12). Interestingly, almost identical re-
sults were obtained for both anti-AibCT3 and anti-CysCT3 IgGs
(Fig. 5). Thus, although the modifications performed influenced
immunogenicity, the fine specificity of the primary IgG response
was apparently unaffected.
The monoclonal IgG response to peptide CysCT3 is
predominantly monospecific but is genetically diverse
To distinguish between narrow range polyspecificity and mono-
specificity, we selected one analogue, peptide CysCT3, for further
study. mAbs of the IgG class were generated using a protocol
identical with that described for peptide PS1CT3 (12). A total of
13 mAbs were obtained, which were subsequently analyzed for
cross-reactivity against the overlapping hexapeptide panel de-
scribed in Figure 5. In addition, we determined the nucleotide se-
quence of the heavy chain variable regions of these mAbs. Results
from both of these studies are summarized in Table I (mAbs Cys2
to Cys23).
Of the 13 mAbs obtained, 12 were directed exclusively against
the DPAF sequence, whereas the remaining one, mAb Cys2, also
FIGURE 3. Relative immunogenicities of peptide PS1CT3 and its an-
alogues. Groups of five BALB/c mice were immunized with peptide
PS1CT3, AibCT3, or CysCT3 as emulsions in CFA (see Materials and
Methods). Twenty-eight days later, the mice were bled, and peptide-spe-
cific serum IgG levels in pooled sera were quantitated by ELISA (see
Materials and Methods). Values presented are the mean of three separate
experiments from independent immunizations.
FIGURE 4. Anti-peptide polyclonal IgG responses are exclusively directed against the B epitope segment. Polyclonal day 28 antisera against peptide
PS1CT3 (A), CysCT3 (B), or peptide AibCT3 (C) from Figure 2 were diluted to 50% of the titer value and incubated with the indicated final concentrations
of either a peptide representing only the homologous B cell epitope (i.e., residues 1–15 of the peptide sequences depicted in Fig. 1A; E) or the homologous
immunogen (i.e., PS1CT3, CysCT3, or AibCT3; F) as described in Materials and Methods. Subsequently, 100-ml aliquots were added in duplicate wells
coated with homologous Ag, and bound Abs were determined by ELISA (see Materials and Methods). The results presented are a representative of three
separate experiments.
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required the leucine residue at position 2 for optimal binding (Ta-
ble I). Analysis of the nucleotide sequences of heavy chain vari-
able regions revealed that these mAbs derive from no less than
seven distinct precursor B cells (Table I). Interestingly, however,
the genetic repertoire of these mAbs appeared to be biased, with as
many as seven mAbs using VH genes from the 36–60 family and
a DH Q52 gene (Table I). In addition, these seven mAbs shared a
highly homologous heavy chain CDR3 region of consensus se-
quence GGTGFXY, where X denotes the sole position of variance
in these regions (Table I).
We next determined the heavy chain nucleotide sequence of the
anti-PS1CT3 mAbs described previously (12), the results of which
are also summarized in Table I (mAbs PC2811 to PC 289). It is
obvious that the monospecific anti-PS1CT3 IgG response similarly
originates from an oligoclonal B cell population, with no less than
four distinct B cell precursors contributing to it (Table I). Intrigu-
ingly, heavy chain variable regions of three of the 11 anti-PS1CT3
IgG mAbs (mAbs PC287, 283, and 289) bore a resemblance to the
dominant anti-CysCT3 mAb population with VH 36–60 and DH
Q52 usage, and a consensus CDR3 sequence of GGTGFXY (Table
I). The substitution of Thr for Ala at position X in mAb 283 vis-
a-vis mAb 289 represents a single nucleotide change in the corre-
sponding codon. It is therefore likely that this change results from
a point mutation as a consequence of somatic hypermutation dur-
ing affinity maturation (24, 25).
The results presented in Table I reiterate that selective immu-
nodominance of the DPAF epitope is retained regardless of
whether it is presented within a linear segment or constrained
within a disulfide-held loop. Further, there is a significant sharing
of the Ab paratope phenotype repertoire between the correspond-
ing mAb populations, at least at the level of the heavy chain vari-
able region.
Affinity for Ag is not a criterion for repertoire distinction
The overlap in repertoires, at least at the level of the heavy chain,
between anti-PS1CT3 and anti-CysCT3 IgG mAbs was intriguing.
If one assumes that fusion is a purely stochastic process, then the
frequency of occurrence of a particular Ab in an mAb panel is also
likely to reflect the frequency of occurrence of the parent B cell in
the Ag-activated B cell pool within the host. If this is true, then the
data in Table I are indicative of a shift in the profile of dominant
paratope phenotypes, at least at the level of the heavy chain, in-
voked by peptides PS1CT3 and CysCT3. Thus, while the heavy
chains used by mAbs PC281, PC282, PC284, PC285, and PC286
constitute the dominant component of the anti-PS1CT3 mAb
panel, it is the heavy chain used by mAbs PC283, PC287, and
PC289 that predominates in the anti-CysCT3 mAb panel, being
present in as many as seven of the 13 Abs (Table I). mAbs anal-
ogous to the remaining anti-PS1CT3 mAbs were not detected in
the anti-CysCT3 panel, indicative either of a relatively lower fre-
quency of occurrence or their absence from it.
Given the altered presentation of the DPAF segment by peptides
PS1CT3 and CysCT3, we expected that the Ab repertoires induced
by each of these Ags should discriminate between the homologous
and heterologous Ags in terms of their binding properties. To as-
sess this, we compared the relative affinities of anti-PS1CT3 and
anti-CysCT3 mAbs for both homologous and heterologous Ags by
FIGURE 5. Monospecificity of the polyclonal day 28 IgG response to
either peptide PS1CT3 or its analogues. Day 28 sera from Figure 2 ob-
tained in response to peptide PS1CT3 (A), CysCT3 (B), or AibCT3 (C)
were screened for IgG cross-reactivity against a panel of overlapping
hexapeptides derived from the homologous B cell epitope segments of
residues 1 to 15 (see Fig. 1A) as previously described (12). The x-axis
denotes each hexapeptide as its N-terminal residue in the parent PS1 se-
quence. The stars on H and N indicate that these positions were substituted
with either Cys (B) or Aib (C) when used to screen for anti-CysCT3 and
anti-AibCT3 cross-reactivities. Results are presented as absorbance ob-
tained for each hexapeptide after subtracting that obtained for a negative
control peptide of sequence AQGNSM. This figure is a representative of
three separate experiments. The serum dilutions used were 1/100 for anti-
PS1CT3 and anti-AibCT3, and 1/50 for anti-CysCT3.
Table I. Characterization of anti-CysCT3 and anti-PS1CT3 IgG mAbs a
mAb
Heavy Chain
CDR3 Sequence
(amino acid)
Minimal Binding
SequencebVH DH JH
Cys-2 36–60 SP2.2 4 EGTSYAMDY LDPAF
Cys-8 J558 SP2.4 3 WDGWLLLFAN DPAF
Cys-18 J558 SP2.3 3 WAWFAY DPAF
Cys-25 7183 SP2.2 3 PYDYDVAWFAY DPAF
Cys–4 J558 FL16.2 4 GRATDYAMDY DPAF
Cys-20 J558 FL16.2 4 GRATDYAMDY DPAF
Cys-16 36–60 Q52 3 GGTGFAY DPAF
Cys-24 36–60 Q52 3 GGTGFAY DPAF
Cys-3 36–60 Q52 2 GGTGFDY DPAF
Cys-7 36–60 Q52 2 GGTGFDY DPAF
Cys-10 36–60 Q52 2 GGTGFDY DPAF
Cys-11 36–60 Q52 2 GGTGFDY DPAF
Cys-23 36–60 Q52 2 GGTGFDY DPAF
PC2811 J558 FL16.1 2 FYY DPAF
PC288 Misc.c SP2.5 4 SGYYGNYVYAMDY DPAF
PC2812 Misc. SP2.5 4 SGYYGNYVYAMDY DPAF
PC281 J558 Q52 2 AGNWDY DPAF
PC282 J558 Q52 2 AGNWDY DPAF
PC284 J558 Q52 2 AGNWDY DPAF
PC285 J558 Q52 2 AGNWDY DPAF
PC286 J558 Q52 2 AGNWDY DPAF
PC287 36–60 Q52 2 GGTGFDY DPAF
PC283 36–60 Q52 3 GGTGFTY DPAF
PC289 36–60 Q52 3 GGTGFAY DPAF
a Nucleotide sequences of the heavy chain variable region genes and identification
of families to which individual segments belong were determined as previously de-
scribed (9). The predicted amino acid sequence of the heavy chain CDR3 region is
also given. Epitope fine specificities of individual mAbs were identified as described
in the text. Gene segment families were identified either with the help of the GenBank
database or by comparison with published sequences (54).
b Ab fine specificity data for the anti-PS1CT3 mAbs were taken from reference 12.
c The VH genes of these mAbs could not be ascribed to any known family and
therefore have been identified as miscellaneous (Misc.).
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competitive inhibition ELISA, and the results are given in Table II.
It is evident that none of the mAbs displayed any significant dif-
ference in affinity for the homologous vs the heterologous peptide
(Table II). This was equally true regardless of whether the mAbs
were generated against peptide PS1CT3 or peptide CysCT3. Thus,
affinity for Ag does not appear to constitute the discriminatory
criterion for repertoire selection by peptide PS1CT3 vis-a-vis that
by its homologue peptide CysCT3.
Clonal relatedness of anti-PS1CT3 and anti-CysCT3 mAbs
employing a common Ig heavy chain
The anti-PS1CT3 and anti-CysCT3 mAbs bearing identical or near
identical heavy chain CDR3 regions could be divided into two
groups on the basis of heavy chain gene segment composition. The
first group included mAbs PC283, PC289, Cys16, and Cys24, all
of which use JH3 in addition to a common DH segment and an
identical member of the 36–60 family of VH genes (Table I). The
only detectable difference represented replacement point muta-
tions, which are likely to have arisen from somatic hypermutations
in the course of the GC reaction (24–28). The second group, in-
volving mAbs PC287, Cys3, Cys7, Cys10, Cys11, and Cys23
could be identified on the basis of utilization of the JH2 gene seg-
ment with the remaining variable region gene segment composi-
tion being identical with that in group I (Table I). However, point
mutational variations leading to amino acid replacements could
again be observed among the mAbs of this group (Table I).
Given that both groups included representatives from the anti-
PS1CT3 and anti-CysCT3 mAb panels, it was of interest to assess
the degree of clonal relatedness between the members of each
group. To this end we determined the nucleotide sequence of the
mAb light chains after first establishing that all the mAbs in these
two groups employed a light chain of the k isotype. The salient
features derived from such an analysis for the mAbs in both groups
are summarized in Table III. With respect to group I, although
mAbs PC283 and PC289 appear to employ a common light chain
it was, nevertheless, distinct from that present in either mAb Cys16
or Cys24 (Table III). These distinctions were readily apparent at
the level of both amino acid sequence of the CDR3 region and JkL
utilization (Table III). Thus, while it is possible that mAbs PC283
and PC289 represent mutational variants of a common precursor,
it is clear that both mAb Cys16 and Cys24 derive from progenitors
that are distinct from each other as well as from that for the anti-
PS1CT3 subset. Nevertheless, given that all four mAbs in this
group use Ig heavy chains with near homologous variable regions
(Table I), at least some degree of structural homology may be
expected at the level of paratope for all four mAbs in this group.
A comparison of light chain variable region nucleotide se-
quences of the group II subset of mAbs revealed that in addition to
sharing derivatives of a common heavy chain variable region, all
these mAbs bore light chains with, barring a few point mutations,
identical variable regions (Table III). The near negligent probabil-
ity of B cells deriving from independent lineages sharing a com-
mon gene segment composition for variable regions of both heavy
and light chains with identical CDR3 regions (29) strongly sug-
gests that mAbs PC287 and the anti-CysCT3 subsets in this group
represent progenitors derived from a common precursor.
Ag discrimination by the anti-CysCT3 and anti-PS1CT3 mAbs is
characterized by differences in the kinetics of recognition
The mAbs described in group I presented an interesting case of
distinct but, nonetheless, structurally homologous anti-DPAF Ab
paratopes independently induced by nonidentical presentation of
the DPAF epitope by peptides PS1CT3 and CysCT3. On the other
Table II. Relative affinities of anti-PS1CT3 and anti-CysCT3 mAbs for
homologous vs heterologous Ags a
mAb Inducing Ag
IC50 (mM) for Peptide
PS1CT3 CysCT3
PC288 PS1CT3 1.8 6 0.5 2.6 6 1.0
PC2812 PS1CT3 2.4 6 0.3 2.8 6 0.8
PC281 pS1CT3 3.3 6 0.4 5.3 6 1.7
PC282 PS1CT3 3.5 6 0.3 4.2 6 0.6
PC284 PS1CT3 3.1 6 0.3 3.4 6 0.2
PC285 PS1CT3 2.8 6 0.8 3.6 6 0.3
PC286 PS1CT3 2.6 6 0.5 2.5 6 0.1
PC287 PS1CT3 1.5 6 0.3 1.2 6 0.2
PC283 PS1CT3 1.4 6 0.4 4.3 6 0.2
PC289 PS1CT3 2.4 6 0.3 4.8 6 0.7
Cys2 CysCT3 1.3 6 0.2 4.1 6 0.6
Cys8 CysCT3 0.6 6 0.2 2.4 6 0.1
Cys18 CysCT3 1.6 6 0.4 4.3 6 0.5
Cys25 CysCT3 5.3 6 0.2 3.9 6 0.8
Cys4 CysCT3 2.0 6 0.7 4.7 6 0.4
Cys20 CysCT3 4.0 6 1.0 6.2 6 0.1
Cys16 CysCT3 1.6 6 0.8 4.9 6 1.0
Cys24 CysCT3 2.9 6 0.6 3.0 6 0.4
Cys3 CysCT3 1.3 6 0.2 3.1 6 0.5
Cys7 CysCT3 1.0 6 0.3 2.8 6 0.4
Cys10 CysCT3 1.6 6 0.6 5.5 6 0.4
Cys11 CysCT3 1.8 6 0.5 5.4 6 1.1
Cys23 CysCT3 1.0 6 0.5 4.4 6 0.5
a Relative affinities were estimated by competitive inhibition ELISA (Materials
and Methods), and data are presented in terms of concentration of each peptide re-
quired to achieve 50% inhibition in Ab binding to surface-absorbed homologous Ag.
Values are the mean (6SD) of three independent determinations.
Table III. Light chain variable region composition of anti-PS1CT3 and anti-CysCT3 mAbs in groups I and II a
Group mAb Inducing Ag
Light Chain (k) Amino Acid Sequence of:
VL JL CDR1 CDR2 CDR3
I PC283 PS1CT3 5 1 KASENVGTYVS GASNRYT GQTYSYP
PC289 PS1CT3 5 1 KASENVGTYVS GASNRYT GQTYSYP
Cys16 CysCT3 5 5 KASENVGTYVS GASNRYT GQSYSHPL
Cys24 CysCT3 3 2 RASKSVSTSGYSYMH LVSNLES QHIRELT
II PC287 PS1CT3 5 5 KASENVDTYVS GASNRYT GQSYSYPL
Cys3 CysCT3 5 5 KASENVGTYVS GASNRYT GQSYSYPP
Cys7 CysCT3 5 5 KASENVGTYVS GASNRYT GQSYSYPP
Cys10 CysCT3 5 5 KASENVGTYVS GASNRYT GQSYSYPP
Cys11 CysCT3 5 5 KASENVGTYVS GASNRYT GQSYSYPP
a Deduced amino acid sequence of the CDR regions of the light chains utilized by the mAbs in groups I and II are given. These were derived from nucleotide sequencing
of the light chain variable region genes as described in Materials and Methods.
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hand, the anti-PS1CT3 and anti-CysCT3 mAbs in group II repre-
sent diversified progeny derived from a single precursor. The oc-
currence of nonidentical replacement mutations in the variable re-
gions of the anti-PS1CT3 vs anti-CysCT3 mAbs suggested that at
least some degree of differential optimization for the variably pre-
sented epitope had indeed taken place. Of particular interest were
two distinctive substitutions that could be noted in the light chain
CDR sequences of these mAbs. The first was the occurrence of the
Asp residue at position 7 of CDR1 in mAb PC287, as opposed to
Gly in the anti-CysCT3 mAbs, and the second was a Leu to Pro
change at position 8 of the CDR3 region (Table III). It is likely that
these distinctive substitutions may have been specified by the con-
fomer of the DPAF epitope against which the respective mAbs
were generated. Consequently, it was surprising that none of the
mAbs in either group displayed a preference for the homologous
Ag in terms of binding affinity, at least when measured as IC50
values (Table II).
To further probe for differences in Ag selectivity, we next de-
termined the on-rates of binding of either peptide PS1CT3 or pep-
tide CysCT3 to the mAbs in both groups by tryptophan fluores-
cence quenching assays. In addition, to eliminate any potential
ambiguities, we estimated the equilibrium dissociation constants
for these interactions using the same technique. The cumulative
data from these experiments are given in Table IV. Although Kd
values for mAb binding to the homologous vs heterologous Ag
were similar, there was a distinct bias in favor of the homologous
peptide when binding on-rates were compared (Table IV). This
was equally true of mAbs in both groups. Thus, in group I, while
the anti-PS1CT3 mAbs PC283 and PC289 bound the homologous
peptide with on-rates that were markedly higher than that for pep-
tide CysCT3. the reverse was true for the anti-CysCT3 mAbs,
Cys16 and Cys24 (Table IV). Similarly, in group II, all anti-
CysCT3 mAbs consistently bound the homologous peptide with
on-rates that were between 14- to 21-fold higher than that for pep-
tide PS1CT3 (Table IV). On the other hand, despite the compara-
ble Kd values, mAb PC287 bound peptide PS1CT3 with an on-rate
that was 62-fold higher than that for peptide CysCT3 (Table IV).
The mAb panels described in groups I and II permit two distinct
levels of analysis. The group I mAbs represent altered repertoire
recruitment as a consequence of presentation of the DPAF epitope
in either a linear or a cyclic segment. On the other hand, the group
II mAbs represent B cell derivatives of a common progenitor, but
with divergent adaptation to the context of DPAF presentation ei-
ther within a linear or a cyclic segment. Thus, the data in Table IV
strongly suggest that kinetic, rather than equilibrium, binding pa-
rameters predominate in defining both Ab repertoire recognition of
an epitope and subsequent maturation in a humoral response.
Discussion
Although surface accessibility is undoubtedly a prerequisite, recent
results (9–13) now suggest that downstream, immune-mediated
mechanisms will also need to be taken into consideration to ex-
plain the hierarchical immunodominance of B cell epitopes on pro-
tein Ags (30–38). An intriguing observation pertaining to this is-
sue was our findings on the immunodominance of the DPAF
sequence in segment PS1 when placed in the context of a variety
of alternate sequences (9, 12). This was found to be independent of
the position of the PS1 sequence in the Ag, the nature of the flank-
ing domains, and also the genetic background of the mouse strain
employed (9–13). Indeed, regardless of the influence of such
changes on the overall immunogenicity of the resulting molecules,
thereby implying quantitative differences in B cell recognition, the
DPAF segment was always the most immunodominant among the
various epitopes presented by the Ag (12). Having previously ruled
out a role for position within the immunogen or nature of flanking
sequence (9, 12), in the present study we sought to explore how
perturbations in the conformational degrees of freedom of the seg-
ment encoding the DPAF epitope would influence its immu-
nodominance relative to the rest of the molecule.
An alteration in the degrees of freedom of the amino-terminal
10-residue segment was alternatively achieved by substitution at
appropriate positions with Aib residues to confer a bias toward
a-helix formation or with cysteine residues to enable subsequent
cyclization. That such substitutions indeed influenced the local en-
vironment within the DPAF epitope could be verified by an anal-
ysis of the 13C NMR spectra of these peptides. An effect on the
immunogenicity of the alterations performed was also observed on
immunization of mice with the resultant analogues. While peptide
AibCT3 yielded primary IgG Abs that were marginally higher than
those against the parent peptide PS1CT3, those against peptide
CysCT3 were markedly diminished. Surprisingly, however, this
effect on immunogenicity did not translate into altered profiles of
relative immunodominance among the putative epitopes contained
within these Ags. The apparent monospecificity of the anti-
CysCT3 response could be further verified by generating mAbs, all
of which were found to be confined to recognition of the DPAF
sequence. Thus, in addition to factors described earlier, the relative
Table IV. Selectivity for the homologous Ag by both group I and II mAbs is evidenced at the level of Ag-
binding kinetics a
Group mAb Inducing Ag
Kd (M) 3 1028
for Peptide
kon (1.m21s21) 3 105
for Peptide
PS1CT3 CysCT3 PS1CT3 CysCT3
I PC283 PS1CT3 2.0 6 0.6 1.4 6 0.8 1.0 6 0.32 0.13 6 0.06
PC189 PS1CT3 5.1 6 1.2 4.8 6 1.7 2.3 6 0.51 0.10 6 0.04
Cys16 CysCT3 3.1 6 0.7 2.8 6 0.6 0.60 6 0.23 5.10 6 0.62
Cys24 CysCT3 3.8 6 0.7 3.3 6 0.7 0.07 6 0.03 1.15 6 0.35
II PC287 PS1CT3 1.8 6 0.9 1.5 6 0.6 5.60 6 0.50 0.09 6 0.03
Cys3 CysCT3 3.2 6 1.2 3.6 6 0.8 1.24 6 0.35 20.00 6 3.20
Cys7 CysCT3 1.6 6 0.4 1.9 6 0.6 2.80 6 0.42 43.00 6 6.40
Cys10 CysCT3 2.8 6 1.6 2.1 6 0.9 2.40 6 0.83 51.00 6 5.30
Cys11 CysCT3 3.8 6 1.4 2.7 6 1.1 2.90 6 0.76 49.40 6 5.50
Cys23 CysCT3 2.4 6 0.4 2.6 6 0.5 0.10 6 0.04 1.45 6 0.24
a Determination of on-rate binding constants (kon) and data presentation are as described in Materials and Methods. Values
are the mean (6SD) of determinations at three separate peptide concentrations. Dissociation constants (Kd) were also obtained
as described in Materials and Methods, and values are the mean (6SD) of three independent determinations.
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immunodominance of the DPAF epitope is also insensitive to per-
turbations in the conformational degrees of freedom available to
the segment within which it is contained. Furthermore, the obser-
vations reported here and previously (12) that preponderance of
the anti-DPAF Ab population was independent of overall immu-
nogenicity strongly imply that parameters involved in defining im-
munogenicity of a multideterminant Ag are independent of those
that influence interepitopic hierarchy on the same Ag.
The analogues described here also provided us with an oppor-
tunity to examine how variations in the conformational freedom of
an epitope qualitatively influence repertoire selection and matura-
tion from the preimmune B cell pool. This was possible since all
three peptides produced, almost exclusively, an anti-DPAF re-
sponse. For this purpose we selected only one of the analogues,
peptide CysCT3, as it was expected that a covalent disulfide-me-
diated ring closure would enforce a greater degree of rigidity as
opposed to Aib substitution. A comparison of the anti-PS1CT3 and
anti-CysCT3 mAb panels revealed that an alteration in the con-
formational propensities of the DPAF epitope did not lead to com-
plete repertoire diversification. Rather, a partial overlap between
the two sets was observed on comparison of the Ig heavy chain
variable regions. This suggests at least some degree of similarity
between the independently derived paratope phenotypes. Although
both the anti-PS1CT3 and anti-CysCT3 mAb panels also included
distinct members, the stochastic nature of the fusion process does
not permit an inference as to whether they represent unique Ag-
specific products or simply reflect differences in clonal population
sizes in in vivo responses to the two Ags.
Considering the fact that peptides PS1CT3 and CysCT3 repre-
sent confomer variants of the same epitope, we had anticipated that
the anti-PS1CT3 and anti-CysCT3 mAbs would display selectivity
in terms of binding behavior for the homologous vis-a-vis heter-
ologous confomer. Surprisingly, this did not hold true on compar-
ison of the relative affinities for the two Ags. No significant dif-
ferences in relative affinity could be detected for the two peptides
with any of the mAbs tested. To investigate further we next se-
lected those anti-PS1CT3 and anti-CysCT3 mAb subsets that
shared a common heavy chain variable region, after accounting for
point mutations as possible derivatives of the somatic hypermuta-
tion pathway in GCs. The underlying rationale for such a selection
was based on the premise that a comparison between homologous
paratope phenotypes would serve as a more reliable and accurate
indicator of nuances in Ag selectivity if any. Such mAbs could
subsequently be segregated into two groups based on the utiliza-
tion of either the JH3 (group I) or the JH2 (group II) gene segment.
By nucleotide sequencing of the light chain variable regions of
mAbs in group I we were able to establish the independent clonal
origins of the two anti-CysCT3 mAbs as well as their nonidentity
with the anti-PS1CT3 mAbs of this group. In contrast, at least
based on gene segment composition and CDR3 regions of both
heavy and light chain variable regions, the mAb panel described in
group II appeared to share a common precursor. Thus, the mAbs
representing both groups seemed to us to provide two levels at
which Ag-driven repertoire discrimination could be examined.
Based on the commonality of the heavy chain variable region but
the diversity in that of the light chain, the anti-PS1CT3 and anti-
CysCT3 mAbs in group I could be considered as a case of a rel-
atively minor Ab paratope repertoire shift in response to the dif-
ferent DPAF confomer variants. On the other hand, the group II
mAbs represented an interesting example of a single precursor Ab
that had divergently adapted to optimally accommodate the variant
epitope confomers presented by peptides PS1CT3 and CysCT3.
The presence of nonidentical replacement mutations in the para-
tope components of the anti-PS1CT3 vs anti-CysCT3 mAbs
strongly suggested that some degree of Ag-specific adaptation had
indeed occurred.
In contrast to the lack of discrimination at the level of affinities,
the facility of epitope recognition, as indicated by binding on-rates,
was found to correlate well with the Ag that was used to elicit a
particular mAb of either group. Thus, for example in group I,
mAbs PC283 and PC289 bound the homologous peptide PS1CT3
with on-rates that were 8- to 23-fold higher than that for the het-
erologous peptide CysCT3. On the other hand, the reverse was true
for mAbs Cys16 and Cys24 where the rate of peptide CysCT3
binding was much higher than that for peptide PS1CT3. Similarly,
a pronounced bias in favor of the homologous confomer, in terms
of binding on-rates, was also noted for the anti-PS1CT3 and anti-
CysCT3 counterparts assigned to group II. This consistent obser-
vation for groups I and II that Ag specificity correlates with the
kinetics of epitope recognition but not with the affinity of it
strongly suggests that both Ag-specified discrimination between
Ab repertoires and Ab optimization for epitope binding, by way of
somatic mutations and subsequent positive selection in GCs, are
under kinetic control. Our latter inference is entirely consistent
with prior studies by Foote and Milstein (39), who have already
demonstrated that intraclonal selection of mutated B lymphocytes
in GCs is kinetically driven. Nevertheless, our results provide an
added perspective in also suggesting that improvement of an Ab-
epitope fit in GCs may primarily represent a kinetic optimization.
While the high affinity of anti-PS1CT3 and anti-CysCT3 mAbs
obtained in the early stages of a humoral response is surprising, it
is consistent with more recent findings in other systems. Thus, for
example, Zinkernagel and co-workers have shown that murine pri-
mary responses to vesicular stomatitis virus is composed of very
high affinity Abs (40). More recently, Smith et al. (41) have dem-
onstrated the presence of high affinity Ab-forming cells in primary
humoral responses to the hapten (4-hydroxy-3-nitrophenyl)acetyl.
Collectively, these studies suggest that optimal affinities for Ag
may be achieved early, perhaps even before recruitment of B cells
within germinal centers (GCs) (40, 41). Under such conditions,
therefore, it may be expected that further optimization of Ag-Ab
binding may be restricted to kinetic considerations.
Although our findings that optimization of the paratope-epitope
fit is regulated by the kinetics of the interaction may appear to
deviate from the common assumption that affinity for Ag plays the
pivotal role (42–46), it is, however, consistent with our current
understanding of the induction and progression of primary T-de-
pendent humoral responses. It is now generally accepted that an
Ag-activated B cell is constantly faced with the opposing choices
of either positive selection for survival or death (47), the deciding
factor being the ability of such B cells to recruit T cell help (10).
Thus, in a competitive environment, such as that presented by GCs
(24–28), where the available pool size of Th cells is limiting, rapid
recruitment of T help by a given B cell is likely to confer on it an
advantage for survival over alternate, competing clonotypes. In-
deed, our own recent results have demonstrated that the quantum
of T cell help recruited by an Ag-activated B cell is proportional to
the on-rate of Ag binding to its sIg receptor (13). This presumably
relates to the rate at which such B cells can generate a high enough
ligand density on the cell surface to ensure TCR triggering above
the requisite threshold value (48, 49). Consequently, it is perhaps
not surprising that those clonal variants in GCs kinetically opti-
mized for epitope binding are the ones that are selected.
The revelation that Ab optimization for epitope conformation is
kinetically determined would also imply that facility of an epitope
fit assumes premium over the perfection of such a fit. This may
explain the high frequency of occurrence of flexible domains on
protein Ags as B cell epitopes (7, 50). Further, this observation
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may serve to rationalize the anomalous findings of imperfect
Ag-Ab interfaces in the x-ray crystal structure of a variety of im-
mune complexes (51, 52).
In summary, the results presented here provide evidence to sup-
port the following inferences. 1) Relative immunodominance of a
peptidic B cell epitope is independent of the conformational con-
straints imposed on it. We stress here again that our interpretation
limits to varying degrees of conformational freedom as opposed to
transitions from one discrete secondary structural form to another.
2) Kinetics override equilibrium binding criteria in mediating Ag-
specified discrimination between alternate possible Ab repertoire
subsets. 3) Positive selection following somatic hypermutation in
GCs is biased in favor of a kinetic optimum. Finally, our studies
reported here also highlight the utility of appropriately designed
model peptide Ags as novel probes to delineate mechanisms reg-
ulating humoral responses.
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